Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Lyra Therapeutics to related businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations.
Volatility & Risk
Lyra Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, Lyra Therapeutics’ rivals have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.
Valuation & Earnings
This table compares Lyra Therapeutics and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lyra Therapeutics | $400,000.00 | -$28.92 million | -0.00 |
| Lyra Therapeutics Competitors | $17.31 billion | $3.17 billion | 560.54 |
Analyst Recommendations
This is a summary of recent ratings and price targets for Lyra Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Lyra Therapeutics Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 30.33%. Given Lyra Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Lyra Therapeutics has less favorable growth aspects than its rivals.
Profitability
This table compares Lyra Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | N/A | N/A | N/A |
| Lyra Therapeutics Competitors | -2,391.71% | -204.89% | -14.89% |
Insider and Institutional Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Lyra Therapeutics rivals beat Lyra Therapeutics on 9 of the 13 factors compared.
About Lyra Therapeutics
Lyra Therapeutics is a U.S.-based biotechnology company that has focused on developing localized treatments for chronic rhinosinusitis, a long-lasting inflammatory condition affecting the nose and sinuses. The company’s investigational candidates, LYR-210 and LYR-220, are bioabsorbable implants designed to deliver mometasone furoate, a corticosteroid, directly to nasal and sinus tissues over an extended period. The treatments were developed for administration by a health care provider, with the goal of providing sustained therapy without relying solely on daily medication.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
